Señales en vivo de PAR.AX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 02:10):

Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia...

Stats
Volumen de hoy	455 715
Volumen promedio	654 560
Capitalización de mercado	94.76M
EPS	$0 ( 2024-02-29 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.170
ATR14	$0.00100 (0.37%)

Volumen Correlación

Largo: 0.09 (neutral)

Corto: 0.91 (very strong)

Signal:(41.025) Expect same movement, but be aware

Paradigm Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Paradigm Correlación - Moneda/Commodity

0.68
( moderate )

0.00
( neutral )

0.13
( neutral )

Paradigm Finanzas

Annual	2023
Ingresos:	$46 760.00
Beneficio Bruto:	$-125 723 (-268.87 %)
EPS:	$-0.180

FY	2023
Ingresos:	$46 760.00
Beneficio Bruto:	$-125 723 (-268.87 %)
EPS:	$-0.180

FY	2022
Ingresos:	$79 224.00
Beneficio Bruto:	$-257 777 (-325.38 %)
EPS:	$-0.160

FY	2021
Ingresos:	$20 550.00
Beneficio Bruto:	$-78 588.00 (-382.42 %)
EPS:	$-0.171

Financial Reports:

No articles found.

Paradigm

Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.